跳转至内容
Merck
CN

MAB3262F

抗BrdU抗体,克隆PRB-1,FITC偶联

clone PRB-1, Chemicon®, from mouse

别名:

BrdU

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
FITC conjugate
Clone:
PRB-1, monoclonal
Application:
FACS
Citations:
5
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


biological source

mouse

Quality Level

conjugate

FITC conjugate

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

PRB-1, monoclonal

species reactivity (predicted by homology)

all

manufacturer/tradename

Chemicon®

technique(s)

flow cytometry: suitable

isotype

IgG1

shipped in

wet ice

target post-translational modification

unmodified

Immunogen

与卵清蛋白结合的碘尿苷。

Application

抗BrdU抗体(克隆PRB-1,FITC偶联)是一种用于检测溴脱氧尿苷(也称为BrdU)的小鼠单克隆抗体,&已在FC中进行了验证。
流式细胞术:1:20

最佳工作稀释度必须由最终用户进行确定。
研究子类别
细胞周期,DNA 复制&修复
研究类别
表观遗传学&核功能

Biochem/physiol Actions

识别ssDNA中的BrdU、游离BrdU或与蛋白载体偶联的BrdU。MAB3262也与碘尿苷反应。不与胸苷反应。

Physical form

与荧光素偶联的纯化免疫球蛋白。 含0.05%叠氮化钠 pH 7.4的PBS液体。

Preparation Note

以未稀释等分试样保存于2-8°C下6个月。避免长时间暴露在光线下。

Other Notes

浓度:请参考批次特异性浓缩物的分析证书。

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

除非我们的产品目录或产品附带的其他公司文档另有说明,否则我们的产品仅供研究使用,不得用于任何其他目的,包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。


Still not finding the right product?

试用我们的 产品选型工具 工具缩小选择范围


存储类别

12 - Non Combustible Liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable



分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



CCN1 induces hepatic ductular reaction through integrin ?v??-mediated activation of NF-?B.
Kim, KH; Chen, CC; Alpini, G; Lau, LF
The Journal of Clinical Investigation null
Johana M Susanto et al.
International journal of oncology, 46(5), 2223-2230 (2015-02-20)
Despite incremental advances in the diagnosis and treatment for pancreatic cancer (PC), the 5‑year survival rate remains <5%. Novel therapies to increase survival and quality of life for PC patients are desperately needed. Epigenetic thera-peutic agents such as histone deacetylase
Songyu Li et al.
Cell death & disease, 11(4), 219-219 (2020-04-07)
DNA damage results in mutations and plays critical roles in cancer development, progression, and treatment. Targeting DNA damage response in cancers by inhibiting poly-(ADP-ribose) polymerases (PARPs) offers an important therapeutic strategy. However, the failure of PARP inhibitors to markedly benefit



全球贸易项目编号

货号GTIN
MAB3262F04053252577802